Barclays initiated coverage of Medline (MDLN) with an Overweight rating and $50 price target The firm likes the company’s scale, private-label differentiation, and logistics capabilities. These create a durable competitive position in the U.S. healthcare supply chain for Medline, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDLN: